Table 4 Adjusted analyses according to type of cancer (AIDS-defining cancer and non-AIDS-defining cancer)
From: Survival after cancer diagnosis in a cohort of HIV-positive individuals in Latin America
ADC | NADC | p (test for interaction) | |||||
|---|---|---|---|---|---|---|---|
Covariate | HR | 95% CI | P | HR | 95% CI | P | |
Sex | 0.08 | 0.86 | 0.18 | ||||
Female (ref) | 1.00 | 1.00 | |||||
Male | 0.67 | (0.43–1.05) | 1.05 | (0.61–1.80) | |||
Cancer diagnosis relative to cART initiation | 0.59 | 0.94 | 0.81 | ||||
Cancer diagnosis after cART (ref) | 1.00 | 1.00 | |||||
Cancer diagnosis before/at cART initiation/Did not start cART | 0.90 | (0.60–1.33) | 1.03 | (0.42–2.52) | |||
CD4 count (cells/μL) at cancer diagnosis | 0.87 | 0.66 | 0.23 | ||||
100 | 1.08 | (0.75–1.55) | 1.09 | (0.81–1.46) | |||
200 | 1.04 | (0.83–1.32) | 1.01 | (0.89–1.15) | |||
350 (ref) | 1.00 | 1.00 | |||||
500 | 0.96 | (0.79–1.18) | 1.05 | (0.90–1.22) | |||
HIV-1 RNA at cancer diagnosis | 0.04 | 0.96 | 0.81 | ||||
Undetectable (ref) | 1.00 | 1.00 | |||||
Detectable (400 copies/mL) | 1.83 | (1.03–3.24) | 0.98 | (0.41–2.30) | |||
Years from HIV diagnosis to cancer diagnosis | 1.04 | (1.00–1.07) | 0.03 | 1.02 | (0.98–1.07) | 0.26 | 0.71 |
Age at cancer diagnosis (per year) | 1.02 | (1.01–1.04) | 0.005 | 1.02 | (1.00–1.04) | 0.12 | 0.70 |